Swati Spentose

What Swati Spentose does

Swati Spentose Pvt. Ltd. is a privately held, family-controlled pharmaceutical manufacturer headquartered in Mumbai, India, with manufacturing operations concentrated in Vapi, Gujarat. The company has operated for over five decades and employs between 251 and 500 people. It produces Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage formulations, with a specialization in carbohydrate chemistry including the commercial production of Pentosan Polysulphate Sodium. Its commercial footprint extends to more than 70 countries, and its facilities hold approvals from USFDA, WHO-GMP, COFEPRIS, Korean MFDS, MHRA, PMDA, EDQM, TGA, and MCC.

The company operates a B2B business model, selling APIs and intermediates to other pharmaceutical manufacturers and distributing finished formulations through direct sales relationships. Named enterprise customers include Macleods Pharmaceuticals, Intas Pharmaceutical, CIPLA, and Sun Pharmaceutical, with some supply relationships dating to 1988. Pricing is quote-based and not publicly disclosed. Swati Spentose differentiates through vertical integration across the pharmaceutical value chain, regulatory compliance across major jurisdictions, and a first-to-market global generic launch of Pentosan Polysulphate Sodium priced at approximately USD 1,200 per treatment versus the originator's USD 25,000. The company also holds patents for treatments targeting kidney-related diseases where no existing medications are available, positioning it in both commoditized generic supply and proprietary therapeutic areas.

Go-to-market relies on direct enterprise relationships, industry trade fair presence, and endorsements from senior leaders of major Indian generic manufacturers. Swati Spentose reports over 25 years of dedicated focus on neglected diseases, and successfully passed a US FDA inspection in 2024 under the leadership of Mr. Vishal Jajodia, continuing the legacy of founder Late Mr. Narayan Jajodia. No external private equity or institutional investor ownership has been disclosed.

Name

Swati Spentose

Legal name

Swati Spentose Pvt. Ltd.

Website

https://spentose.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

251–500 employees

Short description

Swati Spentose is a privately held Indian pharmaceutical manufacturer that produces APIs, intermediates, and finished formulations with expertise in carbohydrate chemistry, selling to pharmaceutical manufacturers across more than 70 countries.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Finished dosage formulations
• Pharmaceutical contract manufacturing
• Generic drug development
• API intermediates supply

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacturing and commercialization of APIs and intermediates sold to other pharmaceutical companies globally.
2. Finished Formulations: Production and commercialization of proprietary finished formulations, extending operations to include production and commercialization of finished dosage forms.
3. Specialty Generic Drugs: First-to-market generic versions of expensive specialty drugs, such as Pentosan Polysulphate Sodium, offered at significantly reduced prices compared to originator products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Swati Spentose manufactures and commercializes Active Pharmaceutical Ingredients (APIs), intermediates, and proprietary finished dosage formulations for pharmaceutical manufacturer customers worldwide. The company operates multiple API and intermediate manufacturing facilities in Vapi, Gujarat, with deep specialization in carbohydrate chemistry, including the commercial production of Pentosan Polysulphate Sodium, and holds patents for kidney-disease treatments. Its offerings are sold B2B to drug makers across more than 70 countries under regulatory approvals including USFDA, WHO-GMP, and cGMP.

Product overview

SWATI is a global research-oriented pharmaceutical company offering a vertically integrated product portfolio spanning the entire value chain from Active Pharmaceutical Ingredients (APIs) and intermediates to finished formulations. The company operates multiple manufacturing facilities in Vapi, Gujarat, and serves clients across more than 70 countries. The core products include APIs (Active Pharmaceutical Ingredients) and Finished Dosage forms, with the company recognized for pioneering generic drug development, including being the first to introduce a generic version of a drug in India at approximately 5% of the original US cost. The company also holds patents for treatments targeting kidney-related diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) and Intermediates Manufacturing and commercialization of Active Pharmaceutical Ingredients and chemical intermediates sold B2B to global pharmaceutical manufacturer clients. Produced at multiple advanced facilities in Vapi, Gujarat, with deep specialization in complex carbohydrate chemistry.
• Finished Dosage Formulations Proprietary finished pharmaceutical dosage forms produced and commercialized by SWATI, extending its vertically integrated offering from API manufacturing through to finished pharmaceutical products for global customers.
• Pentosan Polysulphate Sodium (generic) First-to-market generic version of Pentosan Polysulphate Sodium, an API used to treat kidney-related and interstitial conditions, priced at approximately USD 1,200 per treatment versus the originator's USD 25,000. Produced through SWATI's complex carbohydrate chemistry capabilities and launched globally with partner Intas Pharmaceutical.
• Patented Kidney Disease Treatments Patented pharmaceutical treatments targeting kidney-related diseases, developed by SWATI to address critical therapeutic gaps where no existing medications are available for patients in need.

Quantifiable outcome

• Generic drug pricing at 5% of originator cost (USD 1,200 vs USD 25,000 per treatment)
• +2 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Granules India: Vertically integrated Indian pharma producing APIs and finished dosages (including complex generics) for regulated markets, with overlapping customer profiles and similar manufacturing footprint characteristics.
• Suven Pharmaceuticals: Indian CDMO/API manufacturer with strong regulatory approvals (USFDA, EDQM) and a focus on complex small molecules; comparable regulatory profile and B2B customer model to SWATI.
• Neuland Laboratories: Indian API and contract manufacturer serving global pharma customers, with USFDA-inspected facilities and small-molecule chemistry focus — closely comparable to SWATI's API/intermediates and CMO offerings.
• Aarti Drugs: Indian manufacturer of APIs, intermediates, and formulations serving global generics customers; comparable in scale, customer profile, and product overlap with SWATI's small-molecule and finished-dosage lines.
• Ipca Laboratories: Indian vertically integrated generics manufacturer with API and finished dosage capabilities; comparable in customer profile (other Indian and global generics) and therapeutic areas.
• Aurobindo Pharma: Large Indian vertically-integrated generic manufacturer producing APIs, intermediates, and finished formulations across regulated markets; comparable to SWATI in product mix and B2B pharma customer base, though at significantly larger scale.
• Divi's Laboratories: Indian API and intermediate manufacturer with strong USFDA- and EMEA-compliant facilities, focused on complex generics and custom synthesis — closely comparable to SWATI's API/intermediates business and regulatory positioning.
• Hikal: Indian manufacturer of APIs, intermediates, and contract research services serving global pharma; similar mid-scale, multi-regulatory positioning to SWATI.

Broad incumbents

• Lupin: Large Indian generic manufacturer with API and finished formulation operations across 70+ markets; comparable in scale of geographic reach and vertical integration, though broader in therapeutic scope.
• Sequent Scientific: Indian animal health and API manufacturer; SWATI also produces animal health care products per its short description, making Sequent a relevant broader incumbent in overlapping categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swati Spentose